Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
IND application for EB-003 expected in early 2026
Subscribe To Our Newsletter & Stay Updated